Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.67 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19213003 | 0.84 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP1A2USP30CES2 | |
| SCHEMBL17723948 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL19212925 | 0.80 | CYP11B1 (0.49) | CYP11B1CYP11B2CES2CES1SMN1; SMN2 | |
| SCHEMBL19213007 | 0.74 | CYP11B1 (0.71) | CYP11B1CYP11B2USP30CES2CES1 | |
| SCHEMBL19212943 | 0.73 | CYP11B1 (0.65) | CYP11B1CYP11B2 | |
| SCHEMBL29228749 | 0.71 | CYP11B1 (0.54) | CYP11B1CYP11B2USP30PTGDR2SMN1; SMN2 | |
| SCHEMBL19212928 | 0.71 | CYP11B1 (0.65) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL28209125 | 0.70 | USP30 (0.53) | CYP11B1CYP11B2USP30PTGDR2SMN1; SMN2 | |
| SCHEMBL29826803 | 0.69 | CCR2 (0.56) | CYP11B1USP30PTGDR2TRPM4AR | |
| SCHEMBL16987880 | 0.68 | USP30 (0.49) | CYP11B1CYP11B2USP30PTGDR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885CYP1A2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.